Vaccines targeting different stages of malaria parasites
Official title: mRNA-LNP vaccines targeting multiple stages and multiple species of human malaria parasite
Funded at George Washington University · NIH-11048034 · Data updated 2026-11-12
This study is working on new vaccines that can help protect against malaria by targeting different stages of the malaria parasites, which could lead to better prevention and less spread of the disease for people at risk.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | George Washington University NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project start | December 26, 2024 |
| Project end | November 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $813,160 |
| NIH project number | 1R01AI183533-01A1 |
| Project ID | NIH-11048034 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals living in malaria-endemic regions, particularly in Asia, Africa, and Central and South America.
✕Less likely to help
Patients who do not reside in malaria-endemic areas or those who are not at risk of malaria infection may not benefit from this research.
What this research studies
This research focuses on developing innovative vaccines that target multiple life stages of malaria parasites, specifically Plasmodium falciparum and P. vivax. By creating combination vaccines that address sporozoites and gametocytes, the project aims to enhance immune protection and reduce malaria transmission. The approach includes utilizing specific proteins from the malaria parasites to stimulate a robust immune response. Patients may benefit from these vaccines as they could lead to more effective prevention strategies against malaria.
Why it matters
Potential benefit: If successful, this research could lead to more effective malaria vaccines that significantly reduce infection rates and transmission.
How similar studies have gone: Previous research has shown promise with malaria vaccines targeting specific life stages, indicating potential for success with this novel approach.
Where this research is happening
-
George Washington University
Washington, United States Active
Researchers
- Principal investigator: Kumar, Nirbhay — George Washington University
- Study coordinator: Kumar, Nirbhay
Related research
Other NIH-funded projects on the same topics.
-
Digital malaria surveillance in Ethiopia to improve outbreak detection
A collaboration to add a malaria-specific digital module to an existing surveillance system in Africa to help detect and respond to outbreaks faster.
-
Cross-sector partnership uses digital malaria surveillance in Ethiopia
A US-based team will adapt and test a digital malaria surveillance module in SORMAS to help detect and respond to malaria outbreaks in Ethiopia.
-
Malaria control project in Western Kenya to reduce illness and deaths
A large, multi-year effort in western Kenya will help track malaria spread and test ways to prevent transmission so fewer people get sick or die.
-
Optimizing tafenoquine dose to prevent relapse of vivax malaria in Asia
A study tests the best tafenoquine dose to prevent P. vivax malaria relapse in people in East Asia and Oceania.
-
Optimizing tafenoquine dose to prevent P. vivax malaria relapses in Asia
A study to find the best single-dose tafenoquine amount to prevent relapse of P. vivax malaria in people in East Asia and Oceania.
-
Severe malaria and brain risk in children
This grant studies how severe malaria in young children can affect brain development and long-term thinking and behavior, with a focus on kids in Uganda.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.